DEF: Zimmer Biomet Details 2025 Performance, Governance, and Executive Pay

Zimmer Biomet Holdings, Inc. filed its definitive proxy statement for the 2026 annual meeting, outlining strong 2025 financial performance, executive compensation, and board recommendations on key governance matters.

Summary

• Net sales for 2025 increased by 7.2% over 2024, with a 0.8% positive impact from foreign currency exchange rates.
• The company completed the acquisition of Paragon 28, Inc. on April 21, 2025, expanding into the ~$5 billion foot and ankle orthopedic segment.
• Zimmer Biomet also acquired Monogram Technologies, an AI-driven robotics company, to enhance its robotics suite.
• Key product launches and regulatory authorizations in 2025 included FDA 510(k) clearance of Persona Revision SoluTion Femur, new foot and ankle solutions, and Japan PMDA approval of iTaperloc Complete and iG7 Hip System.
• Executive compensation for 2025 saw annual cash incentive plan payouts ranging from 110.7% to 125.9% of target for named executive officers (NEOs), driven by strong performance against adjusted operating profit and free cash flow targets.
• The 2023-2025 performance-based restricted stock unit (PRSU) awards paid out at 79.6% of target, with constant currency revenue growth (5.4% CAGR) and adjusted EPS growth (6.6% CAGR) exceeding targets, but relative Total Shareholder Return (TSR) at -25.5% significantly underperforming.
• The Board of Directors recommends shareholders vote FOR the election of 10 director nominees, FOR the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026, and FOR the advisory vote on named executive officer compensation.
• The Board recommends shareholders vote AGAINST a shareholder proposal requesting an independent board chairman, citing the importance of flexibility in leadership structure and the robust role of the Lead Independent Director.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting strong internal financial performance and strategic growth initiatives, but tempered by significant underperformance in relative Total Shareholder Return and ongoing legal and reputational challenges highlighted by the shareholder proposal.

Positives

• Net sales increased by 7.2% in 2025 over 2024, demonstrating solid growth despite external headwinds.
• Adjusted operating profit for 2025 achieved 101.5% of its target, reaching $2,263 million against a target of $2,228 million.
• Consolidated free cash flow for 2025 significantly exceeded its target, achieving 151.4% with $1,172 million against a target of $774 million.
• The global quality bonus modifier for the annual cash incentive plan applied at a 2% increase, reflecting zero new FDA warning letters and an average of 1.8 FDA Form 483 observations per inspection.
• Constant currency revenue growth (3-year CAGR) for the 2023-2025 PRSU period was 5.4%, exceeding the target of 4.5%.
• Adjusted EPS growth (3-year CAGR) for the 2023-2025 PRSU period was 6.6%, exceeding the target of 6.1%.
• Strategic acquisitions of Paragon 28, Inc. and Monogram Technologies expanded the company's portfolio into higher-growth markets and advanced robotics.
• The company received regulatory authorizations for several significant product launches, including Persona Revision SoluTion Femur and iTaperloc Complete and iG7 Hip System.
• Zimmer Biomet was recognized as one of the 2025 World's Most Ethical Companies by Ethisphere and one of America's Best Mid-Size Companies by TIME.

Negatives

• Consolidated constant currency revenue for 2025 achieved 99.7% of its target, slightly missing the goal of $8,069 million with an actual of $8,043 million.
• Relative Total Shareholder Return (TSR) for the 2023-2025 PRSU performance period was -25.5%, ranking 21st out of 14 companies in the compensation peer group, resulting in a 0.0% payout for this metric.
• A shareholder proposal highlights a significant stock price drop from $180 in 2021 to $99 in late 2025, despite a robust stock market.
• The shareholder proposal notes ongoing individual lawsuits related to Biomet M2a Magnum and Zimmer Biomet CPT Hip System implants, with the CPT Hip System recalled in July 2024 due to increased fracture risk.
• The company sued its IT provider, Deloitte, for $172 million in September 2025, alleging fraud and breach of contract, which the shareholder proposal suggests may indicate underplayed operational failures.
• The shareholder proposal mentions a lowered full-year adjusted profit forecast in early May 2025, which led to a 10% drop in share price, and Q2 investor letters highlighting lower profit margins compared to peers.

Risks

• Forward-looking statements are subject to significant risks, uncertainties, and changes in circumstances that could cause actual results to differ materially.
• Litigation risks, including patent, product liability, and commercial litigation, could significantly impact operating results.
• Compliance with complex and evolving regulatory requirements, such as the European Union Medical Device Regulation, continues to incur incremental costs.
• Cybersecurity risks, information systems threats, data privacy concerns, and business continuity risks are overseen by the Audit Committee.
• General commercial risks in the musculoskeletal healthcare industry, such as competition, pricing pressures, and the reimbursement landscape, pose ongoing challenges.
• Risks associated with the strategic plan, annual operating plan, capital structure, and complex transactions like mergers, acquisitions, and divestitures.

Future Outlook

The company is confident in its next chapter, aiming to build a durable long-term growth engine with stronger fundamentals and a more specialized go-to-market model. It expects to continue its innovation journey and expand its portfolio of integrated digital and robotic technologies. The company does not expect to incur significant incremental costs related to the European Union Medical Device Regulation starting January 1, 2026.

Management Comments

• "In 2025, we proved that Zimmer Biomet has fundamentally changed – delivering solid growth despite external headwinds, strengthening our portfolio and innovation pipeline, and advancing the people, operational discipline and commercial evolution needed to build a durable long-term growth engine."
• "Looking forward, I am confident we are ready for our next chapter: a company with stronger fundamentals, a more specialized go-to-market model, and a clear mission to alleviate pain and improve quality of life for patients around the world."
• "The Board believes that this leadership structure promotes efficient Board functioning, fosters a constructive and cooperative relationship between the Board and management and reinforces Mr. Tornos' overall responsibility for the company's business and strategy, under the oversight and subject to the review of the Board."

Industry Context

StockSavvy.ai notes that Zimmer Biomet's strategic acquisitions of Paragon 28 and Monogram Technologies align with broader industry trends towards specialization in high-growth segments (foot and ankle) and the integration of digital and AI-driven robotics in medical technology. The company's focus on innovation and global expansion, particularly with regulatory approvals in Japan, reflects a competitive drive in the highly regulated medical device market. The shareholder's concerns about lagging revenue growth, net margin, and return on equity compared to industry averages suggest that while the company is making strategic moves, it faces challenges in translating these into superior financial performance relative to its peers.

Comparison to Industry Standards

• The company's relative Total Shareholder Return (TSR) of -25.5% for the 2023-2025 period significantly underperformed its compensation peer group, ranking 21st out of 14 companies. This indicates a substantial lag compared to competitors like ResMed Inc., Align Technology, Inc., and Intuitive Surgical, Inc., which are also in the medical device and technology space.
• The shareholder proposal highlights an October 2025 analysis suggesting Zimmer Biomet's revenue growth, net margin, and return on equity were lagging behind industry averages, indicating challenges in profitability and efficiency compared to global benchmarks.
• The Board's decision to combine the CEO and Chairman roles, while maintaining a Lead Independent Director, is noted to be consistent with the practice of 57% of the company's compensation peer group companies, and 61% of S&P 500 companies having a lead or presiding director, suggesting alignment with common governance structures in the industry.

Management Changes

Corporate Governance

Legal Proceedings

• Individual lawsuits are still being filed against Zimmer Biomet for injuries related to its Biomet M2a Magnum and Zimmer Biomet CPT Hip System implants.
• The Zimmer Biomet CPT Hip System was recalled in July 2024 after studies found it associated with an increased risk of post-operative thigh bone fractures.
• A September 2024 FDA safety communication regarding the CPT Hip System alerted healthcare providers and patients to the increased fracture risk.
• In September 2025, Zimmer Biomet sued its IT provider, Deloitte, for $172 million, alleging fraud and breach of contract.

Stakeholder Impact

• Shareholders: Impacted by the company's financial performance, executive compensation decisions, and corporate governance structure, including the debate over an independent board chairman.
• Patients: Directly impacted by product safety and quality matters, including the recall of the CPT Hip System and ongoing lawsuits related to implants.
• Employees: Affected by executive succession planning, human capital management policies, and the company's commitment to an inclusive culture.
• Customers (healthcare professionals, Ambulatory Surgery Centers): Benefit from new product introductions, strategic partnerships (e.g., with Getinge), and integrated digital and robotic technologies.
• Regulatory Authorities (FDA, Japan PMDA): Engaged through regulatory authorizations for new products and compliance with medical device regulations.

Next Steps

• The 2026 annual meeting of shareholders will be held virtually on May 22, 2026, where shareholders will vote on director elections, auditor ratification, executive compensation, and a shareholder proposal.
• The Compensation and Management Development Committee will continue to evaluate and refine incentive compensation performance measures, with changes to the annual cash bonus plan weightings effective for 2026.
• The company will continue to engage with shareholders on executive compensation and governance matters throughout the year.

Key Dates

Keywords

Zimmer Biomet, Proxy Statement, Executive Compensation, Corporate Governance, Medical Devices, Orthopedics, Robotics, Acquisitions, Financial Performance, Shareholder Meeting, Risk Management, Board of Directors, SEC Filing